Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant
| Autor: | Jacob Usher, Rebecca Byram, Srilatha Edupuganti, Max W. Adelman, Lilin Lai, Kieffer Hellmeister, Carson Norwood, Dumingu Nipuni Gomes, Venkata Viswanadh Edara, Jesse J. Waggoner, Hayatu Abdullahi, William H. Hudson, Jennifer Kleinhenz, Ahmed Babiker, Mehul S. Suthar, Nina N. McNair, Rebecca Fineman, Garett Michael, Joy Winters, Nadine Rouphael, David S. Stephens, Anne Piantadosi, Katharine Floyd, Lindsay E. Nyhoff, Jamila Pitts, Grace Mantus, Bernadine Panganiban, Nour Beydoun, Evan J. Anderson, Meredith E. Davis-Gardner, Rafi Ahmed, Jens Wrammert, Shivan N. Patel |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Messenger RNA
viral neutralization Coronavirus disease 2019 (COVID-19) SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Brief Report Antibody titer emerging variants Biology Virology Neutralization Titer humoral immunity vaccine biology.protein Antibody receptor-binding domain Neutralizing antibody |
| Zdroj: | Cell Host & Microbe |
| Popis: | The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies. We compared antibody binding and live virus neutralization of sera from naturally infected and Moderna-vaccinated individuals against two SARS-CoV-2 variants: B.1 containing the spike mutation D614G and the emerging B.1.351 variant containing additional spike mutations and deletions. Sera from acutely infected and convalescent COVID-19 patients exhibited a 3-fold reduction in binding antibody titers to the B.1.351 variant receptor-binding domain of the spike protein and a 3.5-fold reduction in neutralizing antibody titers against SARS-CoV-2 B.1.351 variant compared to the B.1 variant. Similar results were seen with sera from Moderna-vaccinated individuals. Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant. Graphical abstract In this study, Edara et al. (2021) report that, despite reduced antibody binding to the B.1.351 RBD, sera from infected (acute and convalescent) and Moderna (mRNA-1273)-vaccinated individuals were still able to neutralize the SARS-CoV-2 B.1.351 variant, suggesting that protective humoral immunity may be retained against this variant. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|